臨床外科78巻1号

2023年01月発行

特集 外科医が知っておくべき！ 免疫チェックポイント阻害薬

総論

免疫チェックポイント阻害薬の有害事象とその対応

著者： 馬場啓介¹ 朴成和¹

所属機関： ¹東京大学医科学研究所附属病院腫瘍・総合内科

ページ範囲：P.12 - P.17

文献概要

【ポイント】
◆癌免疫療法の普及に伴い，免疫関連有害事象（immune-related adverse effect：irAE）の特徴が明らかになりつつある．
◆様々な癌種における様々な免疫チェックポイント阻害薬（ICI）を含む併用療法が行われており，殺細胞性抗癌薬の副作用とirAEの鑑別が重要である．
◆複雑な臨床像を呈するirAEを治療するためには，早期発見と各種専門家による多職種チーム医療が重要である．

参考文献

1）Raschi E, Mazzarella A, Antonazzo IC, et al：Toxicities with immune checkpoint inhibitors：emerging priorities from disproportionality analysis of the FDA adverse event reporting system. Target Oncol 14：205-221, 2019

2）Melson J, Reed D, Horton BJ, et al：Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy. J Clin Oncol 37（suppl）：83-83, 2019

3）Gutzmer R, Stroyakovskiy D, Gogas H, et al：Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma（IMspire150）：primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395（10240）：1835-1844, 2020

4）Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al：KEYNOTE-022 part 3：a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.J Immunother Cancer 8：e001806, 2020

5）Schoenfeld AJ, Arbour KC, Rizvi H, et al：Severe immune-related adverse events are common with sequential PD-（L）1 blockade and osimertinib.Ann Oncol 30：839-844, 2019

6）Schneider BJ, Naidoo J, Santomasso BD, et al：Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy：ASCO guideline update. J Clin Oncol 39：4073-4126, 2021

7）Plachouri KM, Vryzaki E, Georgiou S：Cutaneous adverse events of immune checkpoint inhibitors：a summarized overview. Curr Drug Saf 14：14-20, 2019

8）Sosa A, Lopez Cadena E, Simon Olive C, et al：Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 10：1758835918764628, 2018

9）Chuzi S, Tavora F, Cruz M, et al：Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 9：207-213, 2017

10）Nishino M, Giobbie-Hurder A, Hatabu H, et al：Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer：a systematic review and meta-analysis. JAMA Oncol 2：1607-1616, 2016

11）Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al：Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens：a systematic review and meta-analysis. JAMA Oncol 4：173-182, 2018

12）Lu J, Li L, Lan Y, et al：Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction：a systematic review and meta-analysis. Cancer Med 8：7503-7515, 2019

13）Abdel-Wahab N, Shah M, Suarez-Almazor ME：Adverse events associated with immune checkpoint blockade in patients with cancer：a systematic review of case reports. PLoS One 11：e0160221, 2016

14）Cappelli LC, Gutierrez AK, Baer AN, et al：Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76：43-50, 2017

15）Wanchoo R, Karam S, Uppal NN, et al：Adverse renal effects of immune checkpoint inhibitors：a narrative review. Am J Nephrol 45：160-169, 2017

16）Sznol M, Ferrucci PF, Hogg D, et al：Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35：3815-3822, 2017

17）Cuzzubbo S, Javeri F, Tissier M, et al：Neurological adverse events associated with immune checkpoint inhibitors：review of the literature. Eur J Cancer 73：1-8, 2017

18）Wang DY, Salem JE, Cohen JV, et al：Fatal toxic effects associated with immune checkpoint inhibitors：a systematic review and meta-analysis. JAMA Oncol 4：1721-1728, 2018

19）Feng S, Coward J, McCaffrey E, et al：Pembrolizumab-induced encephalopathy：a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol 12：1626-1635, 2017

20）Kennedy LB, Salama AKS：A review of cancer immunotherapy toxicity. CA Cancer J Clin 70：86-104, 2020

21）Petrelli F, Ardito R, Borgonovo K, et al：Haematological toxicities with immunotherapy in patients with cancer：a systematic review and meta-analysis. Eur J Cancer 103：7-16, 2018

22）Tay RY, Blackley E, McLean C, et al：Successful use of equine anti-thymocyte globulin（ATGAM）for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117：921-924, 2017

23）Heinzerling L, Ott PA, Hodi FS, et al：Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4：50, 2016

24）Johnson DB, Balko JM, Compton ML, et al：Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375：1749-1755, 2016

25）Hussaini S, Chehade R, Boldt RG, et al：Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors ：a systematic review and meta-analysis. Cancer Treat Rev 92：102134, 2021

26）Kang YK, Reck M, Nghiem P, et al：Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase Ⅲ, randomized, controlled trials. J Immunother Cancer 10：e004273, 2022